A new weapon in the global fight against malaria
BASEL, Switzerland--(BUSINESS WIRE)--Malaria is one of the world's most deadly diseases, and it is becoming more pervasive – despite decades of effort and some successes on the path to eradicating it. According to the World Health Organization (WHO), malaria infected 263 million people and killed nearly 600,000 people in 2023 – 75% of whom were children under the age of 5. Of those afflicted, 94% are in Africa – where malaria crushes communities and can cripple economies.
Syngenta launches a next-gen insecticide that takes on the toughest, treatment-resistant mosquitoes. With WHO prequalification, this breakthrough could help save thousands of lives. A global health game changer #WorldMalariaDay #InnovationAgainstMalaria
Share
Spread by parasites in infected mosquitoes that are highly adept at evolving, malaria's rise reflects the reality of insecticide resistance and the difficulties developing new solutions. The effective control of mosquitoes remains a key strategy for reducing disease transmission.
Syngenta, a global leader in agricultural innovation, today announced that its next-generation insecticide Sovrenta ® has received pre-qualification by WHO, paving the way for its use in malaria-afflicted countries. For decades, Syngenta has been at the forefront of the fight against malaria, reflecting its commitment to researching new solutions through in-house R&D efforts and working alongside key partners across sub-Saharan Africa; its products such as Actellic ® already help avert as many as 100 million cases of malaria in more than 30 countries.
Sovrenta ® works by targeting a mosquito's nervous system, blocking signals that enable the insect's muscles to relax. The effect paralyzes the mosquito, so that it eventually dies. The ability of Sovrenta ® to provide long-lasting, effective control means just one application is required each season, reducing the cost for malaria prevention programs.
Sovrenta ® is based on Syngenta's cutting-edge PLINAZOLIN ® technology that features a new mode of action, ensuring effective control of mosquitoes even where the insect's populations are increasingly resistant to older insecticides. When used in rotation with other products, Sovrenta ® can further ensure that important vector control solutions remain effective for longer.
Andy Bywater, Global Head of Marketing for Vector Control at Syngenta Crop Protection, said: 'This marks an important milestone in Syngenta's quest to bring its most advanced innovations to malaria-endemic countries, and to advancing the health and safety of the millions still at risk.'
Bywater said Sovrenta ® is a crucial addition to Syngenta's vector control portfolio that allows for enhanced resistance-management strategies. That is key in regions where mosquitoes are resistant to older insecticides based on pyrethroids – the most common forms of treatment. 'Sovrenta ® is the only insecticide recognized to provide year-long protection and gives malaria control programs a powerful tool to safeguard communities,' Bywater said. 'We are dedicated to collaborating with partners to ensure Sovrenta ® is deployed sustainably and effectively.'
The WHO's Vector Control Product Pre-Qualification (VCPP) is a rigorous process that ensures the safety, efficacy, and quality of vector-borne disease control products. Its list of prequalified vector control products is used by international procurement agencies and by countries to guide bulk purchasing of these products for distribution in resource-limited countries.
Web Resources
About Syngenta
Syngenta is a global leader in agricultural innovation with a presence in more than 90 countries. Syngenta is focused on developing technologies and farming practices that empower farmers, so they can make the transformation required to feed the world's population while preserving our planet. Its bold scientific discoveries deliver better benefits for farmers and society on a bigger scale than ever before. Guided by its Sustainability Priorities, Syngenta is developing new technologies and solutions that support farmers to grow healthier plants in healthier soil with a higher yield. Syngenta Crop Protection is headquartered in Basel, Switzerland; Syngenta Seeds is headquartered in the United States. Read our stories and follow us on LinkedIn, Instagram & X.
Syngenta Vector Control plays a leading role in the prevention of vector-borne disease transmission through its portfolio of mosquito control products. Visit our website and follow us on LinkedIn & X.
Data protection is important to us. You are receiving this publication on the legal basis of Article 6 para 1 lit. f GDPR ('legitimate interest'). However, if you do not wish to receive further information about Syngenta, just send us a brief informal message and we will no longer process your details for this purpose. You can also find further details in our privacy statement.
Cautionary Statement Regarding Forward-Looking Statements
This document may contain forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. For Syngenta, such risks and uncertainties include risks relating to legal proceedings, regulatory approvals, new product development, increasing competition, customer credit risk, general economic and market conditions, compliance and remediation, intellectual property rights, implementation of organizational changes, impairment of intangible assets, consumer perceptions of genetically modified crops and organisms or crop protection chemicals, climatic variations, fluctuations in exchange rates and/or commodity prices, single source supply arrangements, political uncertainty, natural disasters, and breaches of data security or other disruptions of information technology. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.
©2025 Syngenta. Rosentalstrasse 67, 4058 Basel, Switzerland.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Stallergenes Greer Showcases Developments in Respiratory and Food Allergy Care at EAACI 2025
BAAR, Switzerland--(BUSINESS WIRE)--Stallergenes Greer, a global leader in allergy therapeutics, will present insightful scientific developments at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, Glasgow (United Kingdom) June 13-16. The company will present 25 posters and host two scientific symposia during which six world-leading experts will share their insight on respiratory and food allergy: 'Breath of change: redefining respiratory allergy care with remission in sight': with environmental change impacting respiratory allergies, a new approach to disease management is necessary. Clinical remission is emerging as a relevant treatment goal for Type 2 allergies and allergen immunotherapy (AIT) has the potential to cater to this approach. ' Myth busting in peanut allergy: separating fact from fiction ': misconceptions about food allergy management may influence treatment decisions, thus underscoring the vital role of patient-clinician communication. ' We are enthusiastic to share how Stallergenes Greer is bolstering its impact in the field of respiratory and food allergy. Our research findings highlighted at the symposia, as well as through scientific posters and presentations, reflect our determination to deliver innovative allergen immunotherapy solutions that offer sustained benefits for patients worldwide,' stated Dr Elena Rizova, Chief Medical Officer, Stallergenes Greer. ' Our portfolio offers a broad range of proven treatment solutions designed to provide long-lasting relief for patients with allergies across a spectrum of conditions ranging from allergic rhinitis and asthma to food allergy.' The presentation of the posters will showcase Stallergenes Greer's latest research efforts and reaffirm its commitment to advancing personalised allergy care for the benefit of patients and healthcare professionals. Topics include patient benefits with AIT and its potential for clinical remission, new data from the recent real-world study VORAN on 300 IR House Dust Mite (HDM) SLIT tablet, PDAH (defatted powder of Arachis Hypogaea L., semen [peanut]) allergen consistency compared to supermarket peanut products, and prevention of food-induced anaphylaxis in children, including toddlers. SYMPOSIA AND POSTERS COMPANY SPONSORED SYMPOSIUM (June 13, 13:30–14:30 – Room: Meeting Academy M1) "Breath of change: redefining respiratory allergy care with remission in sight" Chair: Prof. Adnan Custovic, United Kingdom - 'Climate, pollution, and the escalating allergy burden: time for a treatment paradigm shift' Speaker: Prof. Guillaume Lezmi, France - 'From symptom control to disease remission: a new vision for allergic asthma' Speaker: Prof. Oliver Pfaar, Germany - 'Allergen immunotherapy: unlocking sustainable relief for allergic rhinitis' Speaker: Prof. Randolph Brehler, Germany COMPANY SPONSORED SYMPOSIUM (June 14, 14:30–15:00 – Room: Boisdale) ' Myth busting in peanut allergy: separating fact from fiction ' Speakers: Dr Aikaterini Anagnostou, United States of America, and Dr Pablo Rodríguez del Río, Spain POSTERS Among the topics covered by the 25 posters, specific findings will be presented and discussed in depth: Recent findings highlight the potential of Stallergenes Greer immunotherapies to provide sustained symptom relief and reduce reliance on corticosteroids even after treatment cessation, aligning with the concept of clinical remission on and off treatment. Evidence from VORAN, the first European real-world data generation study with 300 IR HDM SLIT tablet, supports the safety profile and effectiveness of this treatment in HDM-induced allergic rhinitis with or without controlled asthma in more than 700 adults and adolescents, with over 80% having improved their symptoms and sleep and almost 2/3 stopping nasal corticosteroid use. These findings are further supported by the PRACTIS study, where the benefits of SLIT-liquid met expectations in approximately 90% of patients with allergic rhino conjunctivitis and/or asthma. Furthermore, Stallergenes Greer recently conducted studies showing that its peanut allergy treatment, PDAH, is consistent and offers a positive risk-benefit ratio. Unlike common peanut products found in supermarkets, which can vary in protein and allergen levels, PDAH shows consistency across batches. The research also points to an opportunity to help children from 1 year, when their immune systems may be more adaptable. In clinical studies, the treatment helped reduce the risk of accidental allergic reactions and showed a solid safety record, especially in toddlers. ABOUT THE EAACI CONGRESS The European Academy of Allergy and Clinical Immunology (EAACI) is an association of clinicians, researchers and allied health professionals founded in 1956. EAACI is dedicated to improving the health of people affected by allergic diseases. With more than 16,000 members from 125 countries and over 50 National Allergy Societies, EAACI is the primary source of expertise in Europe and worldwide for all aspects of allergy. Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries. For more information, visit
Business Wire
an hour ago
- Business Wire
Samsung Bioepis Presents Long-Term Safety Data of EPYSQLI™ (Eculizumab) in PNH at the European Hematology Association (EHA) Congress 2025
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. ('Samsung Bioepis') today presented the long-term safety data of EPYSQLI™ (eculizumab; SB12), a biosimilar to Soliris 1, in paroxysmal nocturnal hemoglobinuria (PNH) at the European Hematology Association (EHA) Congress 2025 held at Milan, Italy from June 12 to 15. Long-term follow-up of EPYSQLI's Phase 3 study showed consistency of safety data between the initial 52-week period and the extended treatment period up to 158 weeks Share EPYSQLI was approved by the European Commission (EC) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in May 2023 and March 2024, respectively 2. The study assessed the long-term safety of EPYSQLI in PNH patients by evaluating the consistency of safety outcomes, particularly serious adverse events (SAEs) between the initial 52-week Phase 3 study period and the extended treatment (ET) period, spanning from 52 weeks to up to 158 weeks. The same maintenance dose of 900 mg EPYSQLI was administered every 2 weeks. A total of 46 patients from the Phase 3 study received ET. During ET, seven patients (15.2%) experienced a total of 14 SAEs with no occurrence of fatal cases, and all patients fully recovered without permanently discontinuing the treatment. The exposure-adjusted event rate (EAER) was comparable between initial 52-week period and ET period (EAER were 0.13 and 0.17, respectively), and there was no statistically difference between initial 52-week and ET period in EAER (p-value = 0.76). The study is consistent with the findings of the Phase 3 study with no newly identified safety signals and no fatal cases occurred throughout the entire treatment period with all SAEs resolving completely. Details of the abstract are as follows 3: Abstract title: Long-Term Safety of SB12 in Paroxysmal Nocturnal Hemoglobinuria: Up to 2-year Extension Treatment Safety Data Abstract number: PB2811 Type: Publication Only Session title: Bone marrow failure syndromes incl. PNH – Clinical Author(s): Jun Ho Jang, Siook Baek, Yumin Baek, Jinah Jung, Ciprian Tomuleasa, Hanna Oliynyk, Theerin Lanamtieng, Soo Min Lim Besides approval by the EC, EPYSQLI is also approved by the U.S. Food and Drug Administration (FDA) and Korea's Ministry of Food and Drug Safety (MFDS) as a biosimilar to Soliris. In countries where EPYSQLI is approved and available, EPYSQLI may not be prescribed and/or dispensed for its unapproved other indications for which Soliris is approved. About EPYSQLI (Eculizumab Biosimilar) in the European Union (EU) EPYSQLI is indicated in adults and children for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). EPYSQLI is not approved for and should not be used for the treatment of generalised myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). EPYSQLI must be administered by a healthcare professional and under the supervision of a physician experienced in the management of patients with hematological disorders or renal disorders. EPYSQLI EU Important Safety Information The EU Summary of Product Characteristics for EPYSQLI includes the following Special warning and Precautions: Meningococcal Infection Due to its mechanism of action, the use of eculizumab increases the patient's susceptibility to meningococcal infection (Neisseria meningitidis). Meningococcal disease due to any serogroup may occur. To reduce the risk of infection, all patients must be vaccinated at least 2 weeks prior to receiving eculizumab unless the risk of delaying eculizumab therapy outweighs the risks of developing a meningococcal infection. Patients who initiate eculizumab treatment less than 2 weeks after receiving a tetravalent meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Vaccines against serogroups A, C, Y, W 135 are recommended in preventing the commonly pathogenic meningococcal serogroups. Vaccine against serogroup B where available is also recommended. Patients must receive vaccination according to current national vaccination guidelines for vaccination use. Vaccination may further activate complement. As a result, patients with complement-mediated diseases, including PNH and aHUS, may experience increased signs and symptoms of their underlying disease, such as haemolysis (PNH) or TMA (aHUS). Therefore, patients should be closely monitored for disease symptoms after recommended vaccination. Vaccination may not be sufficient to prevent meningococcal infection. Consideration should be given to official guidance on the appropriate use of antibacterial agents. Cases of serious or fatal meningococcal infections have been reported in eculizumab-treated patients. Sepsis is a common presentation of meningococcal infections in patients treated with eculizumab. All patients should be monitored for early signs of meningococcal infection, evaluated immediately if infection is suspected, and treated with appropriate antibiotics if necessary. Patients should be informed of these signs and symptoms and steps taken to seek medical care immediately. Other Systemic Infections Patients may have increased susceptibility to other type of serious infections, especially with Neisseria and encapsulated bacteria. Infusion Reactions Administration of eculizumab may result in infusion reactions or immunogenicity that could cause allergic or hypersensitivity reactions (including anaphylaxis). Eculizumab administration should be interrupted in all patients experiencing severe infusion reactions and appropriate medical therapy administered. Anticoagulant therapy Treatment with eculizumab should not alter anticoagulant management. PNH Laboratory Monitoring PNH patients should be monitored for signs and symptoms of intravascular haemolysis, including serum lactate dehydrogenase (LDH) levels, and may require dose adjustment within the recommended 14±2 day dosing schedule during the maintenance phase (up to every 12 days). aHUS Laboratory Monitoring aHUS patients receiving eculizumab therapy should be monitored for thrombotic microangiopathy by measuring platelet counts, serum LDH and serum creatinine, and may require dose adjustment within the recommended 14±2 day dosing schedule during the maintenance phase (up to every 12 days). Treatment Discontinuation for PNH If patients discontinue treatment with eculizumab they should be closely monitored for signs and symptoms of serious intravascular haemolysis. Treatment Discontinuation for aHUS If aHUS patients discontinue treatment with eculizumab, they should be monitored closely for signs and symptoms of severe thrombotic microangiopathy complications. The most common adverse reaction observed with eculizumab treatment in clinical trials was headache, (occurred mostly in the initial phase of dosing), and the most serious adverse reaction was found to be meningococcal infection. Refer to the Summary of Product Characteristics for EPYSQLI's full safety information.
Business Upturn
2 hours ago
- Business Upturn
Covid-19 India Cases 2025 Live Updates: Active cases cross 7,000-mark — not Delhi, West Bengal or Maharashtra but this state has most cases
By Aditya Bhagchandani Published on June 12, 2025, 10:07 IST India has seen a fresh rise in Covid-19 infections with active cases crossing the 7,000 mark as of June 12, 2025. The country now has a total of 7,154 active cases, as per data released by the Ministry of Health and Family Welfare. Importantly, six new Covid-related deaths have been reported in the last 24 hours — two from Maharashtra, one from Madhya Pradesh, and three others under review. Kerala leads the chart as worst-hit state Despite no recent headlines from major metros like Delhi, Kolkata, or Mumbai, it is Kerala that continues to top the active caseload in India with 2,165 active cases, accounting for over 30% of the national burden. Gujarat (1,281), West Bengal (747), Delhi (731), and Maharashtra (615) are also witnessing relatively high numbers. New Omicron variants fuelling mild surges Health experts attribute the recent rise to highly transmissible but less severe Omicron sub-variants such as JN.1, NB.1.8.1, LF.7, and XFC. These strains have been classified by the WHO as 'Variants Under Monitoring,' meaning they are not currently considered dangerous but are being tracked closely. Covid becoming part of seasonal cycles While SARS-CoV-2 has not disappeared, its pattern of recurrence has now become more predictable, similar to influenza. The ongoing infections mostly result in milder symptoms, but vulnerable populations are advised to remain cautious and follow preventive protocols. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
